Tretinoin cream to prevent skin rash from EGFR drugs
Part of Cancer clinical trials.
This study tests whether a topical tretinoin cream can prevent the skin rash often caused by anti-EGFR drugs like panitumumab or cetuximab. It is for people with advanced solid tumors who are about to start one of these treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older.
- Have an advanced solid tumor (spread locally or to other parts of the body).
- Be scheduled to receive panitumumab or cetuximab as standard care.
- Be in fairly good physical condition (ECOG score 0–2).
- Have adequate liver and kidney function (specific lab results needed).
- Not have taken an anti-EGFR drug in the past 90 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests repotrectinib (a targeted anti-cancer pill) combined with chemotherapy in children and young adults whose solid tumors have come back or did not respond to standard treatment. The goal is to see how safe the treatment is and whether it can shrink tumors.
This Phase 2 study tests a topical cream (HT-001) to treat skin rashes caused by EGFR inhibitors. It aims to see whether the cream is safe and can reduce rash symptoms and discomfort.
This trial tests a new gel (TAR-0520) for treating a bothersome, acne-like rash that often occurs on the face, scalp, or upper chest during cancer treatment with cetuximab or panitumumab. The goal is to see if it helps reduce the rash without affecting your cancer treatment.
This study tests a new cream, ATR04-484, to see if it can help with skin rashes caused by certain cancer medications (EGFR inhibitors, KRAS inhibitors, or MEK inhibitors). If you have a moderate to severe rash on your face or other areas from these drugs, this trial may offer a new way to ease your symptoms.
This trial tests a new targeted drug (cetuximab β) combined with radiation and chemotherapy for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests whether extra care to prevent skin and infusion side effects helps people with advanced lung cancer who are getting amivantamab (with lazertinib or chemotherapy). It aims to make these treatments easier to tolerate.
Hear when a new Metastatic Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.